BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 14742769)

  • 1. Teriparatide for severe osteoporosis.
    Cappuzzo KA; Delafuente JC
    Ann Pharmacother; 2004 Feb; 38(2):294-302. PubMed ID: 14742769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
    Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
    Orwoll ES; Scheele WH; Paul S; Adami S; Syversen U; Diez-Perez A; Kaufman JM; Clancy AD; Gaich GA
    J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valid treatment options for osteoporosis and osteopenia in HIV-infected persons.
    Clay PG; Voss LE; Williams C; Daume EC
    Ann Pharmacother; 2008 May; 42(5):670-9. PubMed ID: 18413693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid hormone (1-84) and treatment of osteoporosis.
    Shrader SP; Ragucci KR
    Ann Pharmacother; 2005 Sep; 39(9):1511-6. PubMed ID: 16076911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
    Lems WF; Hamdy NA; Netelenbos JC
    Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
    Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of osteoporosis with parathyroid hormone and teriparatide.
    Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K
    Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teriparatide (rhPTH 1-34) for the treatment of osteoporosis.
    Ebeling PR; Russell RG
    Int J Clin Pract; 2003 Oct; 57(8):710-8. PubMed ID: 14627183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis.
    Zanchetta JR; Bogado CE; Ferretti JL; Wang O; Wilson MG; Sato M; Gaich GA; Dalsky GP; Myers SL
    J Bone Miner Res; 2003 Mar; 18(3):539-43. PubMed ID: 12619939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The teriparatide in the treatment of severe senile osteoporosis.
    Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
    Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
    Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating osteoporosis with teriparatide: many unknowns?
    Shukla VK
    Issues Emerg Health Technol; 2003 Nov; (51):1-4. PubMed ID: 14610756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
    Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.